Lantern Pharma prices private placement warrants for 3,669,725 shares at $1.09

The warrants are exercisable only after stockholder approval, with a five-year term from approval, and potential gross proceeds total about $4 million if fully exercised. Closing is expected around Sept. 30, 2026 alongside a $4 million registered direct offering priced at $1.09 per share.